Kenneth Yan
Case Western Reserve University
4 Papers
22 Citations
Kenneth Yan is an academic researcher from Case Western Reserve University. The author has contributed to research in topics: Stem cell & Cancer stem cell. The author has an hindex of 4, co-authored 4 publications. Previous affiliations of Kenneth Yan include Cleveland Clinic Lerner Research Institute.
Chat about Author
Papers
Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy
Kenneth Yan,Qiulian Wu,Diana H. Yan,Christine Lee,Nasiha Rahim,Isabel Tritschler,Jennifer DeVecchio,Matthew F. Kalady,Anita B. Hjelmeland,Jeremy N. Rich +9 more
TL;DR: This study establishes CSC-derived Gremlin1 as a driving force in maintaining glioblastoma tumor proliferation and gliOBlastoma hierarchies through the modulation of endogenous prodifferentiation signals.
The Lgr5 transgene is expressed specifically in glycinergic amacrine cells in the mouse retina
Kumar Sukhdeo,Catherine E. Koch,Tyler E. Miller,Hannah Zhou,Maricruz Rivera,Kenneth Yan,Constance L. Cepko,Justin D. Lathia,Jeremy N. Rich,Jeremy N. Rich +9 more
TL;DR: This work interrogated the spatiotemporal labeling of individual amacrine cells with controlled fluorophore expression and found that this "fluorofilling" technique provides a tool to studyAmacrine morphology and dissect neural networks.
22
Glioma Stem Cell Proliferation and Tumor Growth Are Promoted by Nitric Oxide Synthase-2
Christine E. Eyler,Qiulian Wu,Kenneth Yan,Jennifer MacSwords,Devin Chandler-Militello,Katherine L. Misuraca,Justin D. Lathia,Michael T. Forrester,Jeongwu Lee,Jonathan S. Stamler,Steven A. Goldman,Markus Bredel,Markus Bredel,Roger E. McLendon,Andrew E. Sloan,Anita B. Hjelmeland,Jeremy N. Rich,Jeremy N. Rich +17 more
TL;DR: It is demonstrated that glioma stem cells (GSCs) produce nitric oxide via elevated Nitric oxide synthase-2 (NOS2) expression, providing insight into how GSCs are mechanistically distinct from their less tumorigenic counterparts and suggest that NOS2 inhibition may be an efficacious approach to treating this devastating disease.
The evolving landscape of glioblastoma stem cells.
TL;DR: The last year has witnessed a rapid evolution in the understanding of CSC biology to inform preclinical targeting, spurring a search for anti-CSC therapies that do not disrupt normal stem cell maintenance.